SI2938328T1 - Monolitna farmacevtska oblika za prirejeno sproščanje kombinacije učinkovin - Google Patents

Monolitna farmacevtska oblika za prirejeno sproščanje kombinacije učinkovin

Info

Publication number
SI2938328T1
SI2938328T1 SI201332058T SI201332058T SI2938328T1 SI 2938328 T1 SI2938328 T1 SI 2938328T1 SI 201332058 T SI201332058 T SI 201332058T SI 201332058 T SI201332058 T SI 201332058T SI 2938328 T1 SI2938328 T1 SI 2938328T1
Authority
SI
Slovenia
Prior art keywords
active ingredient
modified release
pharmaceutical form
ingredient combination
monolithic pharmaceutical
Prior art date
Application number
SI201332058T
Other languages
English (en)
Inventor
Francas Gernot
Karl-Heinz Przyklenk
Original Assignee
Hennig Arzneimittel Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE201210113098 external-priority patent/DE102012113098A1/de
Application filed by Hennig Arzneimittel Gmbh & Co. Kg filed Critical Hennig Arzneimittel Gmbh & Co. Kg
Publication of SI2938328T1 publication Critical patent/SI2938328T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201332058T 2012-12-27 2013-12-23 Monolitna farmacevtska oblika za prirejeno sproščanje kombinacije učinkovin SI2938328T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE201210113098 DE102012113098A1 (de) 2012-12-27 2012-12-27 Monolithische Arzneiform zur modifizierten Freisetzung einer Wirkstoffkombination
DE102013101049 2013-02-01
PCT/EP2013/077939 WO2014102253A1 (de) 2012-12-27 2013-12-23 Monolithische arzneiform zur modifizierten freisetzung einer wirkstoffkombination
EP13815516.3A EP2938328B1 (de) 2012-12-27 2013-12-23 Monolithische arzneiform zur modifizierten freisetzung einer wirkstoffkombination

Publications (1)

Publication Number Publication Date
SI2938328T1 true SI2938328T1 (sl) 2023-11-30

Family

ID=49911528

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201332058T SI2938328T1 (sl) 2012-12-27 2013-12-23 Monolitna farmacevtska oblika za prirejeno sproščanje kombinacije učinkovin

Country Status (19)

Country Link
US (1) US20150343067A1 (sl)
EP (1) EP2938328B1 (sl)
KR (1) KR102220130B1 (sl)
AU (1) AU2013369379B2 (sl)
BR (1) BR112015015483A8 (sl)
CA (1) CA2895609C (sl)
EA (1) EA032456B1 (sl)
HU (1) HUE063546T2 (sl)
IL (1) IL239670B (sl)
LT (1) LT2938328T (sl)
MX (1) MX370067B (sl)
PH (1) PH12015501487B1 (sl)
PT (1) PT2938328T (sl)
RS (1) RS64741B1 (sl)
SA (1) SA515360671B1 (sl)
SI (1) SI2938328T1 (sl)
UA (1) UA118099C2 (sl)
WO (1) WO2014102253A1 (sl)
ZA (1) ZA201505084B (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2959887T3 (pl) * 2014-06-26 2019-07-31 Hennig Arzneimittel Gmbh&Co. Kg Środek leczniczy do leczenia zawrotów głowy różnego pochodzenia
CN116134048A (zh) 2020-04-17 2023-05-16 Hb生物科技有限公司 用于治疗神经精神障碍的组合物和方法
WO2022236289A1 (en) * 2021-05-05 2022-11-10 Lyndra Therapeutics, Inc. Gastric residence systems comprising methadone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005014142B4 (de) * 2005-03-23 2006-11-09 Hennig Arzneimittel Gmbh & Co. Kg Pelletförmige Retardzubereitung gegen Schwindel
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
DE102011075354A1 (de) * 2011-05-05 2012-11-08 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur gezielten Freigabe von Wirkstoffen
PT2704698T (pt) * 2011-05-05 2019-11-19 Hennig Arzneimittel Gmbh&Co Kg Forma farmacêutica para a libertação controlada de princípios activos

Also Published As

Publication number Publication date
UA118099C2 (uk) 2018-11-26
PH12015501487A1 (en) 2015-09-21
CA2895609A1 (en) 2014-07-03
CA2895609C (en) 2021-01-12
AU2013369379A1 (en) 2015-07-16
KR20150100734A (ko) 2015-09-02
HUE063546T2 (hu) 2024-01-28
ZA201505084B (en) 2016-12-21
KR102220130B1 (ko) 2021-02-25
AU2013369379B2 (en) 2018-03-15
PT2938328T (pt) 2023-09-26
EA032456B1 (ru) 2019-05-31
BR112015015483A2 (pt) 2017-07-11
IL239670A0 (en) 2015-08-31
EP2938328A1 (de) 2015-11-04
US20150343067A1 (en) 2015-12-03
EP2938328B1 (de) 2023-07-05
RS64741B1 (sr) 2023-11-30
SA515360671B1 (ar) 2022-11-13
PH12015501487B1 (en) 2015-09-21
LT2938328T (lt) 2023-11-27
MX2015008462A (es) 2015-09-23
MX370067B (es) 2019-11-29
IL239670B (en) 2020-08-31
EA201500694A1 (ru) 2015-10-30
BR112015015483A8 (pt) 2019-10-22
WO2014102253A1 (de) 2014-07-03

Similar Documents

Publication Publication Date Title
IL238713A0 (en) Self-regulating active pharmaceutical ingredient release
HK1206270A1 (en) Controlled release formulations for the delivery of hif-1 inhibitors hif-1
IL228441B (en) Controlled-release pharmaceutical dosage forms
HK1223583A1 (zh) 透皮釋放活性物質的系統
IN2015DN03984A (sl)
HK1205462A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
IL236465B (en) Pharmaceutical composition for delayed release of active substances
HK1207285A1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
EP2836206A4 (en) PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE OF DIRECT THROMBINS
ZA201504520B (en) Active ingredient microparticles
IL236466B (en) Pharmaceutical composition for the release of active components
ZA201505084B (en) Monolithic dosage form for the modified release of an active ingredient combination
IL227651A (en) Topical pharmacological formulations containing 220b
PL2585445T3 (pl) Polimorfy aktywnego składnika farmaceutycznego
PT2704698T (pt) Forma farmacêutica para a libertação controlada de princípios activos
SI2474529T1 (sl) Kristalne oblike aktivne farmacevtske učinkovine
TH1401007646A (th) รูปแบบยาเวชภัณฑ์สำหรับการปลดปล่อยส่วนประกอบออกฤทธิ์ (Medicament form for release of active ingredients)